Germany $43 Billion Pharmaceutical Giant Bayer to Buy United States Clinical-Stage Biopharmaceutical Company Perfuse Therapeutics for $2.45 Billion ($300 Million Upfront & $2.15 Billion Contingents) in All-Cash Deal, Perfuse Therapeutics Founded in 2018 by Sevgi Gurkan
11th May 2026 | Hong Kong
Germany pharmaceutical giant Bayer ($43 billion market value) has announced to buy United States clinical-stage biopharmaceutical company Perfuse Therapeutics for $2.45 billion in all-cash deal ($300 million upfront & $2.15 billion contingents). Perfuse Therapeutics was founded in 2018 by Sevgi Gurkan. Perfuse Therapeutics – Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. Bayer – Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros.
“ Germany $43 Billion Pharmaceutical Giant Bayer to Buy United States Clinical-Stage Biopharmaceutical Company Perfuse Therapeutics for $2.45 Billion ($300 Million Upfront & $2.15 Billion Contingents) in All-Cash Deal, Perfuse Therapeutics Founded in 2018 by Sevgi Gurkan “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
Germany $43 Billion Pharmaceutical Giant Bayer to Buy United States Clinical-Stage Biopharmaceutical Company Perfuse Therapeutics for $2.45 Billion ($300 Million Upfront & $2.15 Billion Contingents) in All-Cash Deal, Perfuse Therapeutics Founded in 2018 by Sevgi Gurkan
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
